VHAQ vs. YS, CARM, ASMB, SCYX, LABP, MNOV, SLS, MURA, KRON, and CALC
Should you be buying Viveon Health Acquisition stock or one of its competitors? The main competitors of Viveon Health Acquisition include YS Biopharma (YS), Carisma Therapeutics (CARM), Assembly Biosciences (ASMB), SCYNEXIS (SCYX), Landos Biopharma (LABP), MediciNova (MNOV), SELLAS Life Sciences Group (SLS), Mural Oncology (MURA), Kronos Bio (KRON), and CalciMedica (CALC). These companies are all part of the "pharmaceutical preparations" industry.
Viveon Health Acquisition (NYSE:VHAQ) and YS Biopharma (NASDAQ:YS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, community ranking, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.
In the previous week, YS Biopharma had 5 more articles in the media than Viveon Health Acquisition. MarketBeat recorded 5 mentions for YS Biopharma and 0 mentions for Viveon Health Acquisition. YS Biopharma's average media sentiment score of 1.08 beat Viveon Health Acquisition's score of 0.00 indicating that YS Biopharma is being referred to more favorably in the news media.
YS Biopharma received 1 more outperform votes than Viveon Health Acquisition when rated by MarketBeat users.
Viveon Health Acquisition has a beta of -0.12, indicating that its share price is 112% less volatile than the S&P 500. Comparatively, YS Biopharma has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.
YS Biopharma has a consensus target price of $5.25, indicating a potential upside of 441.24%. Given YS Biopharma's higher probable upside, analysts clearly believe YS Biopharma is more favorable than Viveon Health Acquisition.
Viveon Health Acquisition has higher earnings, but lower revenue than YS Biopharma.
22.1% of Viveon Health Acquisition shares are held by institutional investors. Comparatively, 52.6% of YS Biopharma shares are held by institutional investors. 75.3% of Viveon Health Acquisition shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
YS Biopharma beats Viveon Health Acquisition on 8 of the 10 factors compared between the two stocks.
Get Viveon Health Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for VHAQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VHAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viveon Health Acquisition Competitors List
Related Companies and Tools
